Emylcamate
From Wikipedia, the free encyclopedia
 |
|
|
Emylcamate
|
|
| Systematic (IUPAC) name | |
| 3-methyl-3-pentanol carbamate | |
| Identifiers | |
| CAS number | 78-28-4 |
| ATC code | N05BC03 |
| PubChem | 6526 |
| Chemical data | |
| Formula | C7H15NO2 |
| Mol. weight | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Emylcamate (marketed as Striatran® by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.
[edit] References
- Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia (Portuguese)
- The Comparative Toxicogenomics Database: Emylcamate.
- BIAM: Emylcamate (French).
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
